Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Lymphoid 1Genitourinary 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Solitary Pulmonary Nodule 1Smoking Cessation 1Multiple Pulmonary Nodules 1Mesothelioma 1Lymphoma, B-Cell 1Lung Neoplasms 1Cigarette Smoking 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Pemetrexed 10Cisplatin 9Gemcitabine 8Nivolumab 5Ipilimumab 4Carboplatin 4niraparib 3durvalumab 3Vinorelbine 3Bevacizumab 3tremelimumab 2pembrolizumab 2olaparib 2anetumab ravtansine 2Radiotherapy, Intensity-Modulated 2Oxaliplatin 2Imatinib Mesylate 2Hyperthermic Intraperitoneal Chemotherapy 2Fluorodeoxyglucose F18 2Cytoreduction Surgical Procedures 2vandetanib 1tislelizumab 1tazemetostat 1spartalizumab 1sargramostim 1ribociclib 1fludarabine phosphate 1fludarabine 1dostarlimab 1defactinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Mesothelioma × 4-(3-fluoropropyl)glutamic acid × Clear all
NCT02599194 2019-01-03

18F-FSPG PET/CT for Cancer Patients on Therapy

Stanford University

Phase 2 Completed
7 enrolled 6 charts
BreastGenitourinaryLymphoidOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Lymphoma, B-Cell, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡